الصفحة الرئيسية>>Signaling Pathways>> Metabolism>> Phospholipase>>LY 178002

LY 178002

رقم الكتالوجGC30610

LY 178002 هو مثبط قوي لـ 5-lipoxygenase (5-LPO) ، فسفوليباز A2 ، مع IC50 0.6 ميكرومتر لـ 5-ليبوكسيجيناز ، يمنع الإنتاج الخلوي لـ LTB4 بواسطة كريات الدم البيضاء متعددة الأشكال البشرية ، ويظهر تثبيطًا ضعيفًا نسبيًا على انزيمات الأكسدة الحلقية

Products are for research use only. Not for human use. We do not sell to patients.

LY 178002 التركيب الكيميائي

Cas No.: 107889-32-7

الحجم السعر المخزون الكميّة
1mg
184٫00
متوفر
5mg
368٫00
متوفر
10mg
625٫00
متوفر
20mg
1103٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

LY 178002 is a potent inhibitor of 5-lipoxygenase, phospholipase A2, with IC50 of 0.6 μM for 5-1ipoxygenase, inhibits cellular production of LTB4 by human polymorphonuclear leukocytes, and shows relatively weak inhibition on cyclooxygenase.

LY178002 inhibits the generation of LTB4, PLA2 and FCO with IC50s of 0.1, 6.3 and 4.2 μM [1].

LY 178002 (50 mg/kg) inhibits soft tissue swelling in the uninjected paw by 81%, and inhibits bone damage in rats. The minimum effective dose for LY178002 is 10 mg/kg p.o. In the established FCA model LY178002 at 50 mg/kg p.o. inhibits the uninjected paw swelling by 75%[1].

[1]. Panetta JA, et al. The anti-inflammatory effects of LY178002 and LY256548. Agents Actions. 1989 Jun;27(3-4):300-2.

مراجعات

Review for LY 178002

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for LY 178002

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.